Navigation Links
Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug

Samaritan Announces Positive Data in Nonclinical (IND) In- Vitro Studies for Promising Alzheimer's Drug

LAS VEGAS, May 3, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce positive results were attained with its late-stage preclinical/nonclinical testing of Caprospinol (SP-233), with well recognized in-vitro models.

Although nonclinical research results are imperfect predictors of clinical responses, laboratory animals remain the best experimental models for identifying and measuring a compound's biological activity and for predicting a drug's clinical effects. Because animal studies are performed before and during clinical studies, the term "nonclinical" is generally preferred to preclinical when discussing the full spectrum of in-vitro and non-human in-vivo tests associated with drug development. By studying a drug's dose-response characteristics, adverse and residual effects, Samaritan and the FDA gain valuable insights, as to a drug's probable action, and effect in humans.

Samaritan completed a series of in-vitro studies to determine SP-233's metabolic stability in liver microsomes. SP-233's results were positive since it was reported to be stable in all four species tested: human, dog, rat and mouse species. The metabolic stability of a drug candidate, e.g., drug substance in liver microsomes of different species, is determined in order to assess the potential of SP-233 to form undesired potentially toxicity or pharmacologically inactive metabolites.

In addition, positive results were reported where SP-233 was shown to have no CYP inhibition potential for CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 suggesting that SP-233, is unlikely to cause, or alter the metabolism of co-administered drugs, and thus cause, a drug-drug interaction, which could give rise to severe side effects.

Dr. Janet Greeson, CEO of Sam
'"/>




Page: 1 2 3

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... in Advanced-Illness ... COLLEGEVILLE, Pa. and TARRYTOWN, N.Y., May 28 ,Wyeth Pharmaceuticals, ... Inc. (Nasdaq: PGNX ) today announced the publication of,results ... injection in the May 29, 2008 issue of the New,England ...
... Robert Brackett, chief,science officer for the Grocery Manufacturers ... the findings on childhood,and teen obesity rates reported in ... Association (JAMA):, "We welcome the findings reported in ... (JAMA) indicating that the rise in,childhood and teen obesity ...
Cached Medicine Technology:New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study 2New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study 3New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study 4New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study 5New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study 6New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study 7
(Date:12/22/2014)... 22, 2014 Coral Gables is preparing to ... Lice Troopers, with its new clinic location set to open ... the hassle out of dealing with this common childhood parasite ... their two salon clinic locations in South Florida, or in ... The decision to expand developed naturally out of the demand ...
(Date:12/22/2014)... International efforts to combat ... are receiving further support from recent initiatives ... (NGOs) and other charitable organizations. While research ... responders, patients and others can immediately benefit ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... 22, 2014 Super Saturday, the last ... year as the busiest day in the 2014 holiday ... Grass Station had a steady pre-Christmas stream of customers, ... past Saturday. , “I definitely intend to take advantage…of ... Denver resident who was enjoying The Grass Station’s holiday ...
(Date:12/22/2014)... The MedTech industry is gearing up for new growth and ... AB of Sweden, is prepared to facilitate the manufacturing expansion ... All signs point to growth in the MedTech industry with ... of the excise tax originally levied to fund the ... of 9.3% and PartnerTech Inc. is prepared to answer the ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... of ER visits jumps 11% compared to average day, ... to U.S. hospital emergency departments related to underage drinking rise ... days, a new report finds. , The Drug Abuse Warning ... who combine alcohol and illegal drugs are 27 percent more ...
... treatment in monkeys offers hope for humans, researchers say , ... disrupted the ability of the Ebola virus to replicate in ... with the lethal disease. , The study is the first ... exposure to the Ebola virus. Previous research showed that it ...
... , ... Histogen, Inc., a regenerative ... cells grown under embryonic conditions, will present findings today at ... Assessment of bioengineered, human extracellular matrix (hECM)-coated polymers showed ...
... Kate Lee, a veteran ... to create an online forum that allows current and prospective egg donors the opportunity to dialogue ... ... six egg donations, has partnered with Beverly Hills Egg Donation, a leading egg donor agency, to ...
... ... from 11 a.m. – 3 p.m. , ... (PRWEB) May 28, 2010 -- Timed to tip off National Physical Fitness & Sports Month in ... markets through the joint efforts of participating cable affiliates. Comcast Spotlight in Seattle has partnered with ...
... ... Health & Fitness Expo at the Fargo Marathon in Fargo, North Dakota. , ... Fargo, ND (Vocus) May 28, 2010—For the third consecutive year, ... Marathon in Fargo, North Dakota. The 2010 Swanson Health & Fitness Expo ran from ...
Cached Medicine News:Health News:Human Extracellular Matrix Significantly Improves Device Biocompatibility 2Health News:Human Extracellular Matrix Significantly Improves Device Biocompatibility 3Health News:Six-Time Egg Donor Creates "Ask Kate", an Online Forum to Help Future Egg Donors 2Health News:Cartoon Network's MOVE IT MOVEMENT TOUR Stops in Seattle Market 2Health News:Cartoon Network's MOVE IT MOVEMENT TOUR Stops in Seattle Market 3Health News:Cartoon Network's MOVE IT MOVEMENT TOUR Stops in Seattle Market 4Health News:Swanson Health & Fitness Expo at the Fargo Marathon 2
The ImagingPlanet 70 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgical micr...
... Optronics MicroFire - Monochrome: An ... microscope camera with Firewire connectivity. ... imaging beyond 900nm. The camera ... a C-mount adapter and is ...
... the most technologically advanced Micro-dermabrasion machine ... USA after extensive research, it offers ... with maximum control and total flexibility ... to traditional methods because the complex ...
The Urine Legionella Antigen ELISA kit detects the presence of Legionella pneumophila serogroup1 antigen in urine....
Medicine Products: